We are updating our Privacy Policy and Terms and Conditions to help you clearly understand how your personal information is collected, stored and managed. Learn More
Menu Back toCardiac-Safety-in-Drug-Development-and-the-Critical-Role-of-Public-Private-Partnerships-The-Cardiac-Safety-Research-Consortium-Model

DIA 2018 Global Annual Meeting

The DIA 2018 Global Annual Meeting brings together thousands of innovators from around the globe.

Cardiac Safety in Drug Development and the Critical Role of Public-Private Partnerships: The Cardiac Safety Research Consortium Model

    Session Chair(s)
      Rick  Turner, DrSc, PhD

      Rick Turner, DrSc, PhD

      • President
      • Turner Consulting and Communications LLC, United States
    This session will discuss how the Cardiac Safety Research Consortium’s collaborative, precompetitive approach has significantly advanced the field of cardiac safety in medical product development. Industry, academia, and regulatory perspectives will be provided.
    Learning Objective : Discuss the concept and implementation of Public-Private Partnerships; Recognize the importance of cardiac safety considerations throughout new drug development; Describe new approaches to regulatory science in cardiac safety.
      Mitchell W. Krucoff, MD

      The Cardiac Safety Research Consortium: Current Accomplishments and Future Goals

      Mitchell W. Krucoff, MD

      • Professor of Medicine/Cardiology
      • Duke University, United States
      Norman  Stockbridge, MD, PhD

      New Approaches to Regulatory Science in Cardiac Safety

      Norman Stockbridge, MD, PhD

      • Director, Division of Cardiovascular and Renal Products, OND, CDER
      • FDA, United States
      Philip T. Sager, MD

      The Comprehensive In-Vitro Proarrhythmia Assay (CiPA)

      Philip T. Sager, MD

      • Adjunct Professor
      • Stanford University, United States